Long-term real-world follow-up of adults with cutaneous squamous cell carcinoma needing systemic treatment in France

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a non-interventional, multicenter study that builds a national database of patients with cutaneous squamous cell carcinoma who start first-line systemic therapy for curative, adjuvant, or neoadjuvant intent. It combines retrospective data from January 2020 onward with a prospective phase to describe clinical characteristics, effectiveness, and safety of systemic treatments in routine practice. The project aims to illuminate how treatment strategies are evolving as management of advanced cSCC changes. Approximately 30 centers from the French Cutaneous Oncology Group participate under the University Hospital of Lille as lead sponsor, with collaborations from industry and patient foundations. It does not involve assigning treatments but rather observing and recording outcomes in real-world settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a diagnosis of primary cutaneous squamous cell carcinoma initiating first-line systemic therapy, whether administered with curative, adjuvant, or neoadjuvant intent.

  * Male or female patients.
  * Age ≥18 years.
  * No documented objection to participation in the study.

Exclusion Criteria:

* Patients who refuse to participate in the study or who object to the collection or processing of their personal data.
* Initiation of systemic therapy prior to 2020.
* Patients not requiring systemic therapy.
* More than one line of systemic therapy at the time of inclusion.
* Patients under legal guardianship or curatorship.
* Individuals deprived of liberty.
* lack of health insurance coverage.

Where it's running

• Centre Hospitalier Régional d'Orléans
  Annecy, France Recruiting
• CHRU Besançon
  Besançon, France Recruiting
• Centre Hospitalier de Blois
  Blois, France Recruiting
• Hôpital Avicenne
  Bobigny, France Recruiting
• Hôpital Saint André,
  Bordeaux, France Recruiting
• Hôpital Ambroise Paré
  Boulogne-Billancourt, France Recruiting

Study contacts

• Study coordinator: Laurent MORTIER, PU-PH
• Email: laurent.mortier@chu-lille.fr
• Phone: 33 3 20 44 41 93

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Seeing if the first lymph node helps detect skin cancer spread earlier

  They are testing whether checking the sentinel lymph node early can help see if high-risk skin squamous cell cancer has started to spread.

  Recruiting Germans Trias i Pujol Hospital · Badalona, Barcelona · NCT07746258

• First-in-human test of KUP-101A in selected advanced skin cancers

  This early study tests KUP-101A to see if it's safe and tolerable and to gather initial clues about its activity in patients with advanced skin cancers.

  Recruiting at 3 sites Phase 1 Kupando GmbH · Munich, Bavaria and 2 other locations · NCT07600476

• Topical 5% Niacinamide for Skin Cancer Prevention in Organ Transplant Recipients

  This trial tests whether applying a 5% niacinamide cream daily, in addition to sunscreen, can reduce actinic keratoses and new skin cancers in adults who have had an organ transplant.

  Recruiting at 2 sites Early Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania and 1 other locations · NCT07286318

• Next‑generation immune profiling to find response and toxicity markers in skin cancer patients treated with cemiplimab

  This project will test whether advanced blood and tumor immune profiling can help predict who with advanced cutaneous squamous cell carcinoma will benefit from cemiplimab and who may develop side effects.

  Recruiting Instituto de Investigación Biomédica de Salamanca · Salamanca, Salamanca · NCT07064330

• MOHs Surgery and Short-Course Radiation for Head & Neck Skin Cancer

  This study tests whether a short course of radiation after Mohs surgery can prevent recurrence in high-risk cases, and whether some patients with moderate risk can be safely monitored without radiation.

  Recruiting Phase 2 University of Vermont Medical Center · Burlington, Vermont · NCT06998342

• Evaluating the impact of post-operative radiotherapy on high-grade skin cancer

  This study is testing if getting radiation therapy after surgery helps people with high-grade skin cancer live longer and have fewer recurrences compared to those who don't get the treatment.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia, Pavia · NCT06879964

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.